mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is a critical problem in the treatment of EGFR mutant lung cancer. Several mechanisms, including bypass signaling by hepatocyte growth factor (HGF)-triggered Met activation, are implicated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ishikawa, Daisuke, Takeuchi, Shinji, Nakagawa, Takayuki, Sano, Takako, Nakade, Junya, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Nakamura, Takahiro, Matsumoto, Kunio, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Yano, Seiji
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3653905/
https://ncbi.nlm.nih.gov/pubmed/23690929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0062104
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים